Cequa®
Cyclosporine 0.09% · ophthalmic solution
Dry Eye/OSD
Approved uses
Keratoconjunctivitis sicca (dry eye)
One drop BID in each eye, approximately 12 hours apart
Sign improvement on corneal staining begins at day 28 and builds through day 84, without symptom relief.
Contraindications
None.
0.09% (0.9 mg/mL) preservative-free solution, 0.25 mL single-use vials, box of 60 vials dispensed intact
Cyclosporine is a calcineurin inhibitor immunosuppressant when administered systemically. In patients whose tear production is presumed to be suppressed due to ocular inflammation associated with keratoconjunctivitis sicca, topical cyclosporine is thought to act as a partial immunomodulator. The exact mechanism of action is not known. In healthy subjects given twice daily dosing into each eye for up to 7 days, blood concentrations were either not detectable or marginally above the lower limit of assay quantitation of 0.100 ng/mL (range 0.101 to 0.195 ng/mL).
Warnings & Precautions
- Eye injury and contamination: To avoid the potential for eye injury and contamination, advise patients not to touch the vial tip to the eye or other surfaces.
- Use with contact lenses: Should not be administered while wearing contact lenses; remove lenses before administration, and lenses may be reinserted 15 minutes afterward.
Common Side Effects
The most common adverse reactions, reported in greater than 5% of subjects, were pain on instillation of drops (22%) and conjunctival hyperemia (6%). Other adverse reactions reported in 1% to 5% of patients were blepharitis, eye irritation, headache, and urinary tract infection.
Pregnancy: No adequate and well-controlled studies in pregnant women. Oral cyclosporine was not teratogenic in rats or rabbits at clinically relevant doses; teratogenicity appeared only at maternally toxic doses roughly 3200 and 21000 times the maximum recommended human ophthalmic dose.
Lactation: Blood concentrations after topical dosing are low, and there is no information on presence in human milk after topical administration or on effects on the breastfed infant or milk production. Oral cyclosporine given to rats during lactation produced no adverse effects in offspring at clinically relevant doses. Weigh the developmental and health benefits of breastfeeding with the mother's clinical need for the drug and any potential adverse effects on the breastfed child.
Safety and efficacy not established below age 18.